AdaptHealth (AHCO) PT Lowered to $9 at Baird

Thu, 17 Sep 2026 07:11:02 -0400

Baird analyst Eric Coldwell lowered the price target on AdaptHealth (NASDAQ: AHCO) to $9.00 (from $10.00) while maintaining a Outperform rating.

Form 4 AdaptHealth Corp. For: Sep 09 Filed by: CURRIE HARRISS T

Fri, 11 Sep 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260911/27053000.html

Form 3 AdaptHealth Corp. For: Sep 09 Filed by: CURRIE HARRISS T

Fri, 11 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260911/27052986.html

AdaptHealth To Participate in Upcoming Investor Conferences

Fri, 11 Sep 2026 13:00:00 -0400

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today announced today that they will participate in the following upcoming investor conferences:

The 2026 Jefferies Healthcare Services and Technology Conference, being held in Nashville, on Monday, September 14, 2026, including a fireside chat at 10:55am CST. Attendees for the Company will be Suzanne Foster, Chief Executive Officer, Harriss Currie, Chief Financial Officer, and Luke Montgomery, SVP Investor Relations.

Webcast link: https://event.summitcast.com/view/GhCtEPrzrHFSChRnGR9UnE/J8rNDcZRzSgeSJhRGmvNtj

AdaptHealth To Participate in Upcoming Investor Conferences

Fri, 11 Sep 2026 13:00:00 -0400

The 2026 Jefferies Healthcare Services and Technology Conference, being held in Nashville, on Monday, September 14, 2026, including a fireside chat at 10:55am CST. Attendees for the Company will be Suzanne Foster, Chief Executive Officer, Harriss Currie, Chief Financial Officer, and Luke Montgomery, SVP Investor Relations.

Webcast link: https://event.summitcast.com/view/GhCtEPrzrHFSChRnGR9UnE/J8rNDcZRzSgeSJhRGmvNtj

Truist Securities on AdaptHealth (AHCO) Amid CFO Change

Wed, 09 Sep 2026 08:23:46 -0400

Truist Securities analyst David MacDonald reiterated a Buy rating and $9.00 price target on AdaptHealth (NASDAQ: AHCO).

The analyst commented: "CFO Change Announced. After the close, AHCO filed an 8-K announcing the appointment of Harriss Currie as the company's CFO effective 9/9 with former CFO Jason Clemens assisting in the transition through 10/1. The announcement comes on the heels of disappointing recent results and a challenging 2Q marked by a sizable core guidance cut (excluding Diabetes divestiture impact) tied largely to underperformance within the large Kaiser capitated contract and a manufacturer price increase. Mr. Currie brings meaningful public company experience and

AdaptHealth names Harriss Currie as CFO, effective Sept. 9

Tue, 08 Sep 2026 16:00:15 -0400

AdaptHealth Corp. (NASDAQ: AHCO) has appointed Harriss T. Currie as Chief Financial Officer, effective September 9, 2026, according to a company statement.

Currie will succeed Jason Clemens, who will remain with the company through October 1, 2026 to assist with the transition.

Currie brings experience from several CFO roles in the healthcare sector. He served as CFO of Luminex Corp (NASDAQ: LMNX) for more than 15 years until the company was acquired by DiaSorin in 2021. He subsequently held CFO positions at Impulse Dynamics from 2022 to 2023 and Health Track Rx from 2025 to 2026, and served as President of the

AdaptHealth names Harriss Currie as CFO, effective Sept. 9

Tue, 08 Sep 2026 16:00:15 -0400

AdaptHealth Corp. (NASDAQ: AHCO) has appointed Harriss T. Currie as Chief Financial Officer, effective September 9, 2026, according to a company statement.

Currie will succeed Jason Clemens, who will remain with the company through October 1, 2026 to assist with the transition.

AdaptHealth names Harriss Currie as CFO, effective Sept. 9

Tue, 08 Sep 2026 16:00:15 -0400

AdaptHealth Corp. (NASDAQ: AHCO) has appointed Harriss T. Currie as Chief Financial Officer, effective September 9, 2026, according to a company statement.

Currie will succeed Jason Clemens, who will remain with the company through October 1, 2026 to assist with the transition.

ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health